<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384631</url>
  </required_header>
  <id_info>
    <org_study_id>8414</org_study_id>
    <nct_id>NCT00384631</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Neovascular Glaucoma</brief_title>
  <acronym>IVB NVG</acronym>
  <official_title>Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in
      eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other
      neovascular disorders such as wet-type age-related macular degeneration and diabetic macular
      edema has been described. We aim to evaluate the effect of three intravitreal injections of
      bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures
      include intraocular pressure and extent of iris neovascularization. Both study arms will
      receive conventional treatment for NVG.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intraocular pressure</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in extent of iris neovascularization</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Neovascular</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>subconjunctival normal saline</intervention_name>
    <description>0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>intravitreal injection of avastin 2.5mg repeated twice at monthly intervals</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of NVG

          -  Vision less than 20/200

          -  age 10-80 years

        Exclusion Criteria:

          -  Uncontrolled Blood Pressure

          -  History of thromboembolism

          -  Congestive Heart Failure

          -  Renal Failure

          -  Pregnancy or Lactation

          -  Active ocular or periocular infection

          -  No light perception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahin Yazdani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center, Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Labbafinejad Medical Center</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2006</study_first_submitted>
  <study_first_submitted_qc>October 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>February 14, 2008</last_update_submitted>
  <last_update_submitted_qc>February 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2008</last_update_posted>
  <keyword>Neovascular</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>Intravitreal</keyword>
  <keyword>IOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

